



## Astria Therapeutics to Participate in Upcoming Investor Conferences

March 9, 2022

BOSTON--(BUSINESS WIRE)--Mar. 9, 2022-- [Astria Therapeutics, Inc.](#) (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE), today announced that the Company will be participating in two upcoming investor conferences:

- Oppenheimer's 32<sup>nd</sup> Annual Healthcare Conference: On March 17, 2022 at 12:40pm ET, Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview and provide information on lead program STAR-0215.
- Guggenheim Healthcare Talks, 2022 Genomic Medicines and Rare Disease: Astria Therapeutics will be participating in the conference, which will take place on March 31 and April 1, 2022.

A live webcast of the Oppenheimer presentation can be accessed at the following link: <https://wsw.com/webcast/oppenheimer20/atxs/2810304>. An archived replay of the presentation will be available in the investors section of [www.astriatx.com](http://www.astriatx.com) for 30 days following the event.

### About Astria Therapeutics:

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Learn more about our company on our website, [www.astriatx.com](http://www.astriatx.com), or follow us on Twitter and Instagram @AstriaTx and on Facebook and LinkedIn.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20220309005065/en/): <https://www.businesswire.com/news/home/20220309005065/en/>

Astria Contacts:

### Investor relations:

Andrea Matthews  
[investors@astriatx.com](mailto:investors@astriatx.com)

### Media:

Elizabeth Higgins  
[media@astriatx.com](mailto:media@astriatx.com)

Source: Astria Therapeutics, Inc.